Trulieve Cannabis Corp. · Medicinal Chemicals & Botanical Products

TRLV

Moderate riskNext report: Due any day

View price ↗

The short version

A company still losing money with shrinking sales.

Watch out for

Sales down 10% in the latest quarter vs a year ago
Losing money

Money moves

No insider buying or selling in the last 30 days

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$10.82+4.0% that day

Company value: $2.1B; Share price times all shares
Price vs sales: 1.8x; No profit over the last year, so this compares value with sales instead
Cash vs value: 16%; Cash as a share of company value
Debt vs value: 7%; Debt as a share of company value

From TRLV's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$271.0M-10% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $1.1B, down 3.9% from the 12 months before. Over 5 years, sales grew about 18% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of TRLV. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth-4% a yearRecently: -3.9% a yearProfit margin10%Last 12 months: -41.3%P/E at the end15xMany steady companies trade at 12x to 25xShare count change+1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$929M

Profit in 5 years$93M

Price these guesses point to$6.89-36% vs $10.82 todayAbout -8.6% a year, before dividends

What today's price needs: with a 10% margin and a 15x P/E, sales would have to grow about 5.1% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

2/5Weak

MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-9.9%
MissProfitable every yearSteady profits, not one good year.3 of 7 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$228.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+1.8% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.60.2%

Revenue: $1.2B; -0.4% vs prior year
5-year growth: +17.8%/yr; revenue, per year
Total debt: $136.7M
Current ratio: 4.43x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, debt under half of equity. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported May 7

Revenue: $271.0M; -10.3% YoY
Op. margin: -136.7%; -154.1 pts
Gross margin: 59.9%; -0.7 pts
Free cash flow: $32.1M
Share count: +0.8%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.5
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Newly held

Institutions held almost none of it the quarter before (new listing, spin-off or ticker change), so there's no fair percent change yet. 120 bought, 3 sold. 2 quarters of net buying in a row.

Shares held by institutions38.8M

Sep '24Jun '26